Previous studies have indicated that XDY could inhibit the overreaction of TLR, PKC and inflammasome pathways to exert therapeutic efficacy on viral pneumonia induced by IAV challenge [30–32, 34]. The gene discussed is PRRT2; the disease is viral pneumonia.